FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for Patients with BRAF V600E-mutated mCRC By Ogkologos - January 24, 2025 423 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BREAKWATER study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Coping with Grief: An Interview with Author Rebecca Munn September 28, 2020 FDA Approves Cemiplimab-rwlc for Locally Advanced and Metastatic Basal Cell Carcinoma February 12, 2021 Anal Cancer Incidence and Deaths Are Rising in the United States December 19, 2019 Professor Eithne Costello: On the road to early detection November 12, 2021 Load more HOT NEWS New on NCI’s Websites for September 2021 What Is Intuitive Eating and How Can It Help During Cancer? Post-Mastectomy Boutique Set to Close After 12 Years, As Owner Has... Science Surgery: ‘Can cancers develop in the heart?’
